Perfil
Demetrios Kydonieus is the founder of R-Pharm US LLC, which was founded in 2014, where he holds the title of President.
He is currently an Independent Director at Invea Therapeutics, Inc. since 2021.
Mr. Kydonieus's former positions include Director at Amylin Pharmaceuticals, Inc. in 2012 and President & Director at Inhibitex LLC.
Cargos activos de Demetrios Kydonieus
| Empresas | Cargo | Inicio |
|---|---|---|
R-Pharm US LLC
 R-Pharm US LLC Pharmaceuticals: MajorHealth Technology R-Pharm US LLC engages in development and commercialization of medicines to treat cancer. Its products include IXEMPRA and episil. The company was founded by Mark Pavao and Demetrios Kydonieus in 2014 and is headquartered in Princeton, NJ. | Fundador | 01/01/2014 |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Director/Miembro de la Junta | 01/11/2021 |
Antiguos cargos conocidos de Demetrios Kydonieus.
| Empresas | Cargo | Fin |
|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Director/Miembro de la Junta | - |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Presidente | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
R-Pharm US LLC
R-Pharm US LLC Pharmaceuticals: MajorHealth Technology R-Pharm US LLC engages in development and commercialization of medicines to treat cancer. Its products include IXEMPRA and episil. The company was founded by Mark Pavao and Demetrios Kydonieus in 2014 and is headquartered in Princeton, NJ. | Health Technology |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT. | Health Technology |
- Bolsa de valores
- Insiders
- Demetrios Kydonieus